Immunoprecise Antibodies Ltd.'s Polytope TATX-03 antibody combination therapy has been shown to neutralize SARS-CoV-2 variants of concern, including the omicron BA.5 subvariant, in an authentic virus assay.
Academy of Military Medical Sciences (AMMS) has divulged 3C-like proteinase (viral) and 3C protease (viral) inhibitors reported to be useful for the treatment of viral infections.
Scientists have discovered a new antibiotic called evybactin that is able to selectively target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) lung infections. As described in NatureChemicalBiology on Aug. 22, 2022. the work is still at an early stage and requires further validation. But, if successful in clinical trials, evybactin could form part of a new group of specific antibiotics designed to target TB.
he continuing emergence of immune-evasive variants of SARS-CoV-2 virus represents a major challenge in controlling COVID-19 pandemic disease. Researchers from Stanford University have tested the immunogenicity and protective effect of the receptor binding domain (RBD)-I53-50 AS03-adjuvanted nanoparticle vaccine in nonhuman primates.
In the search for novel antibacterial agents, some targets have been engaged to kill Gram-positive but not Gram-negative organisms, due to lack of accumulation of proposed agents.
Interim analysis of a phase III trial testing a single dose of Pfizer Inc.'s bivalent respiratory syncytial virus (RSV) vaccine candidate, RSVpreF, in older adults has revealed efficacy good enough to support a planned BLA submission for the vaccine to the U.S. FDA in fall 2022, the company said. Preparation for further submissions to other regulatory agencies are underway.
Scientists have discovered that the enzyme aconitate decarboxylase 1 is not an anti-inflammatory mediator in sepsis. In the presence of bacterial toxins, it is involved in the cytokine storm and inflammatory signaling in monocytes and macrophages, becoming a potential therapeutic target against the infection.
RSS
